U-3570

TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS